Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma Journal Article

Authors: Emmanouilides, C.; Witzig, T. E.; Gordon, L. I.; Vo, K.; Wiseman, G. A.; Flinn, I. W.; Darif, M.; Schilder, R. J.; Molina, A.
Article Title: Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
Abstract: Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL. Data on 211 patients treated in four clinical trials were analysed to compare the efficacy and safety of 90Y ibritumomab tiuxetan when it was used after the first relapse of NHL and when it was used after two or more prior therapies. Sixty-three patients (30%) were treated with 90Y ibritumomab tiuxetan after their first relapse and 148 (70%) after two or more prior therapies. Demographics, disease characteristics and the frequency of adverse events were similar in all groups, with the exception of a higher rate of marrow involvement in first-relapse patients than in patients with two or more prior therapies (57% vs. 39%; P < 0.05). The complete response rate [confirmed (CR) and unconfirmed (Cru)] was higher in first-relapse patients (49% vs. 28%; P< 0.01), and the median time to progression (TTP) was longer (12.6 vs. 7.9 months; P < 0.05). In patients with follicular NHL, the differences were even more pronounced (CR/CRu: 51% vs. 28%; P < 0.01; TTP: 15.4 vs. 9.2 months; P < 0.05). 90Y ibritumomab tiuxetan has substantial clinical benefits as a second-line therapy, especially in patients with follicular NHL. The quality of disease remissions obtained when 90Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients. © 2006 Taylor & Francis.
Keywords: adult; cancer chemotherapy; controlled study; human tissue; aged; aged, 80 and over; middle aged; major clinical study; clinical trial; disease course; neutropenia; drug efficacy; drug safety; ibritumomab tiuxetan; rituximab; radiopharmaceuticals; demography; controlled clinical trial; infection; anemia; thrombocytopenia; recurrence; abdominal pain; asthenia; dyspnea; b cell lymphoma; lymphoma, b-cell; antibodies, monoclonal; nonhodgkin lymphoma; non-hodgkin's lymphoma; lymphoma, non-hodgkin; remission induction; cancer relapse; safety; purine derivative; anthracycline derivative; corticosteroid; radioimmunotherapy; yttrium radioisotopes; hematologic disease; efficacy; frequency analysis; disease activity; bone marrow metastasis; first relapse
Journal Title: Leukemia and Lymphoma
Volume: 47
Issue: 4
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2006-04-01
Start Page: 629
End Page: 636
Language: English
DOI: 10.1080/10428190500376076
PUBMED: 16690521
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 51" - "Export Date: 4 June 2012" - "CODEN: LELYE" - "Source: Scopus"
Citation Impact